Gloria Vigliani

3.3k total citations
8 papers, 782 citations indexed

About

Gloria Vigliani is a scholar working on Infectious Diseases, Epidemiology and Urology. According to data from OpenAlex, Gloria Vigliani has authored 8 papers receiving a total of 782 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 6 papers in Epidemiology and 2 papers in Urology. Recurrent topics in Gloria Vigliani's work include Antimicrobial Resistance in Staphylococcus (6 papers), Infective Endocarditis Diagnosis and Management (6 papers) and Periodontal Regeneration and Treatments (2 papers). Gloria Vigliani is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (6 papers), Infective Endocarditis Diagnosis and Management (6 papers) and Periodontal Regeneration and Treatments (2 papers). Gloria Vigliani collaborates with scholars based in United States, Lebanon and France. Gloria Vigliani's co-authors include Sara Yankelev, Mark Benvenuto, David P. Benziger, Donald P. Levine, Helen W. Boucher, Elías Abrutyn, G. Ralph Corey, Henry J. Mankin, Vance G. Fowler and Adolf W. Karchmer and has published in prestigious journals such as Journal of Clinical Investigation, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Gloria Vigliani

8 papers receiving 737 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gloria Vigliani United States 8 517 310 274 224 119 8 782
Andrea Restrepo Colombia 13 143 0.3× 162 0.5× 80 0.3× 58 0.3× 75 0.6× 22 637
Tara L. Anderson United States 14 398 0.8× 176 0.6× 276 1.0× 155 0.7× 5 0.0× 26 696
Randall W. Strate United States 7 315 0.6× 112 0.4× 179 0.7× 49 0.2× 10 0.1× 12 556
Marta Herrero Spain 12 78 0.2× 155 0.5× 124 0.5× 48 0.2× 74 0.6× 33 481
Abby Douglas Australia 15 333 0.6× 251 0.8× 67 0.2× 484 2.2× 79 0.7× 40 917
Wen‐Tsung Lo Taiwan 18 289 0.6× 292 0.9× 115 0.4× 24 0.1× 14 0.1× 40 790
Teresa Tórtola Spain 14 195 0.4× 434 1.4× 46 0.2× 66 0.3× 72 0.6× 39 870
M. Christofidou Greece 14 73 0.1× 258 0.8× 70 0.3× 60 0.3× 57 0.5× 25 573
Hee Joo Lee South Korea 14 163 0.3× 191 0.6× 41 0.1× 82 0.4× 14 0.1× 41 574
Ibai Los‐Arcos Spain 17 181 0.4× 378 1.2× 47 0.2× 100 0.4× 27 0.2× 47 686

Countries citing papers authored by Gloria Vigliani

Since Specialization
Citations

This map shows the geographic impact of Gloria Vigliani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gloria Vigliani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gloria Vigliani more than expected).

Fields of papers citing papers by Gloria Vigliani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gloria Vigliani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gloria Vigliani. The network helps show where Gloria Vigliani may publish in the future.

Co-authorship network of co-authors of Gloria Vigliani

This figure shows the co-authorship network connecting the top 25 collaborators of Gloria Vigliani. A scholar is included among the top collaborators of Gloria Vigliani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gloria Vigliani. Gloria Vigliani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Kanafani, Zeina A., Helen W. Boucher, Vance G. Fowler, et al.. (2010). Daptomycin compared to standard therapy for the treatment of native valve endocarditis. Enfermedades Infecciosas y Microbiología Clínica. 28(8). 498–503. 16 indexed citations
2.
Kanafani, Zeina A., Wissam M. Kourany, Vance G. Fowler, et al.. (2009). Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis. European Journal of Clinical Microbiology & Infectious Diseases. 28(12). 1477–1482. 33 indexed citations
3.
Cosgrove, Sara E., Gloria Vigliani, Marilyn Campion, et al.. (2009). Initial Low‐Dose Gentamicin forStaphylococcus aureusBacteremia and Endocarditis Is Nephrotoxic. Clinical Infectious Diseases. 48(6). 713–721. 198 indexed citations
4.
Rehm, Susan J., Helen W. Boucher, Donald P. Levine, et al.. (2008). Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. Journal of Antimicrobial Chemotherapy. 62(6). 1413–1421. 87 indexed citations
5.
Lalani, Tahaniyat, Helen W. Boucher, Sara E. Cosgrove, et al.. (2007). Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy. 61(1). 177–182. 50 indexed citations
6.
Benvenuto, Mark, David P. Benziger, Sara Yankelev, & Gloria Vigliani. (2006). Pharmacokinetics and Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body Weight Once Daily in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 50(10). 3245–3249. 257 indexed citations
7.
Ehrlich, Michael G., et al.. (1978). Correlation between articular cartilage collagenase activity and osteoarthritis. Arthritis & Rheumatism. 21(7). 761–766. 54 indexed citations
8.
Ehrlich, M G, et al.. (1977). Collagenase and collagenase inhibitors in osteoarthritic and normal cartilage.. Journal of Clinical Investigation. 59(2). 226–233. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026